https://www.targetedonc.com/view/brentuximab-vedotin-shows-promising-activity-as-first-line-use-in-classical-hodgkin-lymphoma
0
0
10/17/22 at 4:02pm
Organization
Targetedonc.com
Author
Ariana Pelosci
39 words
0
Comments
At the NCCN Annual Congress:Hematologic Malignancies, David J. Straus, MD debated if this was the best course of action for treating Hodgkin lymphoma.
You are the first to view
Create an account
or login to join the discussion